ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.55 CNY | +0.47% |
|
-1.61% | -8.75% |
| May. 13 | Fengyuan Pharma Gets Nod to Register Two Dialysis Solutions | MT |
| Apr. 25 | Anhui Fengyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 4B 553M | Sales 2023 | 4.28B 590M | Capitalization | 3.11B 429M |
|---|---|---|---|---|---|
| Net income 2022 | 154M 21.25M | Net income 2023 | 159M 21.95M | EV / Sales 2022 | 1.2 x |
| Net Debt 2022 | 304M 41.89M | Net Debt 2023 | 368M 50.77M | EV / Sales 2023 | 0.81 x |
| P/E ratio 2022 |
27.8
x | P/E ratio 2023 |
19.5
x | Employees | 4,670 |
| Yield 2022 |
0.74% | Yield 2023 |
1.6% | Free-Float | 69.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.47% | ||
| 1 week | -1.61% | ||
| 3 months | +13.70% | ||
| 6 months | -16.99% | ||
| Current year | -8.75% |
1 week
8.44
8.70
1 month
8.449.10
Current year
5.969.60
1 year
5.9611.16
3 years
5.9616.98
5 years
5.5416.98
10 years
4.7619.99
| Managers | Title | Age | Since |
|---|---|---|---|
Tian Le Ru
CEO | Chief Executive Officer | 39 | 07-08-31 |
Jun Li
DFI | Director of Finance/CFO | 47 | 08-10-31 |
Yue E Hu
CHM | Chairman | 62 | 07-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Man He
CHM | Chairman | 52 | 08-03-17 |
Zhen Hong Lu
BRD | Director/Board Member | 49 | 16-03-27 |
Jun Zhang
BRD | Director/Board Member | 54 | 98-10-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 8.55 | +0.47% | 3,450,719 |
| 24-05-30 | 8.51 | +0.35% | 6,919,400 |
| 24-05-29 | 8.48 | +0.12% | 4,283,800 |
| 24-05-28 | 8.47 | -2.64% | 6,267,700 |
| 24-05-27 | 8.7 | +0.12% | 7,057,500 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, manufacture and distribution of biological medicines, chemical synthetic medicines and Chinese medicines. The Company's products mainly include antipyretic and analgesic, women and children, the nervous system, cardiovascular, urinary system, nutrition, antibiotics and active ingredient and other products. The Company is also engaged in the retailing and wholesale of drugs. The Company conducts its businesses mainly in domestic markets, with Anhui province as its main market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.75% | 392M | |
| +40.73% | 739B | |
| +31.70% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.38% | 240B | |
| +9.47% | 210B | |
| -5.44% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 000153 Stock
